MILANO (Italy) / NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem cell gene therapies for cancer (Temferon™), today announced that the Company is scheduled to present on October 08, 2019 at: Chardan Genetic 3rd Medicines
MILANO (Italy) / NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem cell gene therapies for cancer (Temferon™), today announced the closing of its third Round adding €13,2M in a total of €30,2M since incorporation.
Milan (Italy), March, 7th 2019 – MolMed S.p.A. (“MolMed”, MLMD.MI), clinical stage biotechnology company focusing on research, development, manufacturing and clinical validation of cell & gene therapies for the treatment of cancer and rare diseases, and Genenta Science, (“Genenta”), biotechnology
Guido Guidi, M.D. joined the Board of Directors, prof. Kenneth C. Anderson, M.D. joined the Scientific Advisory Board, and a new office at Alexandria LaunchLabs®, NYC has been opened. Milano (Italy), Sept. 13, 2017 . Genenta Science, a biotech company committed to the development and
Milan (Italy), Jan. 19, 2017. Genenta Science, a biotech company focused on hematopoietic stem cell gene therapy for tumor treatment, today announced that Carlo Russo, M.D. is joining the company as Chief Medical Officer. Dr. Russo comes to Genenta from Adverum Biotechnologies, where he served as
Genenta Science and San Raffaele Hospital and Scientific Institute (Ospedale San Raffaele, OSR) today announced a research collaboration agreement with Amgen to evaluate the efficacy of novel gene therapy strategies for tumor treatment. The collaborative agreement brings Genenta, OSR and Amgen
Milan (Italy), Jan. 19, 2017. Genenta Science, a biotech company focused on hematopoietic stem cell gene therapy for tumor treatment, today announced that Carlo Russo, M.D. is joining the company as Chief Medical Officer. Dr. Russo comes to Genenta from Adverum Biotechnologies, where he served as
Milan, January 23rd, 2015. In less than five months since its foundation, GENENTA SCIENCE raised Euro 6.2 million (USD 7.2 million). The funding campaign was backed by Banca Esperia, the private bank of Mediobanca (ticker: MB at Milan Stock Exchange) and Mediolanum (MED at Milan Stock Exchange).
Milan, March 5th, 2015. After a few weeks from the first closing, GENENTA SCIENCE banked an overall Euro 10.0 million (USD 11.0 million) Series A round, the company target. The funding campaign was supported by Banca Esperia, the Private Bank of Mediobanca (MB:IM) and Mediolanum (MED:IM).
